Insights from Prothena's Q4 2024 call highlight 2025 milestones: pivotal trial results for birtamimab & Alzheimer's programs.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, reports dose-escalation approval for tuspetinib, ...

We recently compiled a list of the 12 Best Get Rich Fast Stocks To Buy Now. In this article, we are going to take a look at ...

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...

Apimeds Pharmaceuticals US (APUS) is planning to raise $20 million in an initial public offering on the week of February 24th, IPO Scoop reports. The company will be issuing 4,500,000 shares at ...

Personalised mRNA vaccines have shown positive results as pancreatic cancer treatment, a phase 1 clinical trial found.

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light ...